THE FIRST TROP-2-DIRECTED ADC: TRODELVY DELIVERS A POTENT TOPOISOMERASE 1 INHIBITOR TO mTNBC TUMORS1
Trop-2 is a surface protein frequently expressed by many cancers, including approximately 90% of TNBC tumors2*
Trop-2 biomarker testing is not required for use with TRODELVY
TRODELVY binds to the antigen Trop-2 and delivers and concentrates a potent cytotoxic into tumor tissue3
The proposed mechanism of action is based on preclinical data, which may not correlate with clinical outcomes.
Humanized monoclonal antibody1Binds to Trop-2, the trophoblast cell-surface antigen-2
- Links the humanized monoclonal antibody to SN-38
- Hydrolysis of the linker releases SN-38 to kill tumor cells
Cytotoxic1The payload of TRODELVY is SN-38, a topoisomerase inhibitor that prevents repair of DNA damage and leads to apoptosis and cell death
TRODELVY has a high drug-to-antibody ratio, with an average of 7 to 8 molecules of SN-38 per antibody molecule.1
- ADCs use a monoclonal antibody to deliver an attached cytotoxic drug into tumors4
- Pharmacology data suggest that, once inside the tumor, the linker connecting the antibody to the cytotoxic is cleaved, releasing the active drug4
*As measured by immunohistochemical (IHC) assay.